Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.

Abstract

Aim: Comparison of tapentadol prolonged release (PR) with other oral WHO-III PR opioid analgesics (morphine, oxycodone ± naloxone, hydromorphone) in routine medical care of chronic low back pain. Patients & methods: Noninterventional, retrospective 12-week study using anonymized clinical practice data from the German Pain eRegistry. Six effectiveness, tolerability, and safety criteria were aggregated in a primary composite end point (treatment responder). Propensity scoring matched 2331 datasets per treatment cohort. Results: All six single criteria showed significantly better outcomes for tapentadol PR (all parameters p < 0.001). There were significantly more treatment responders under tapentadol PR (65.7 vs 14.2%; p < 0.001). Conclusion: Tapentadol PR showed significantly better effectiveness and tolerability in severe chronic low back pain unsuccessfully treated with WHO-I/II analgesics compared with the other oral WHO-III PR opioids investigated.

• Authors: Michael A Überall, Christian Elling, Christoph Eibl, Gerhard Hh Müller-Schwefe, Claudia Lefeber, Myriam Heine, Birgit Heckes
• Journal: Pain management (Pain Manag) Vol. 12 Issue 2 Pg. 211-227 (Mar 2022) ISSN: 1758-1877 [Electronic] England
• PMID: 34376059 (Publication Type: Journal Article)

Chemical References

• Analgesics, Opioid
• Delayed-Action Preparations
• Phenols
• Tapentadol

Topics

• Analgesics, Opioid (therapeutic use)
• Chronic Pain (drug therapy)
• Delayed-Action Preparations
• Humans
• Low Back Pain (drug therapy)
• Phenols (therapeutic use)
• Retrospective Studies
• Tapentadol (therapeutic use)